valsartan

Summary

Summary: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.

Top Publications

  1. Disertori M, Latini R, Barlera S, Franzosi M, Staszewsky L, Maggioni A, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360:1606-17 pubmed publisher
    ..We conducted a large, randomized, prospective, placebo-controlled, multicenter trial to test whether the ARB valsartan could reduce the recurrence of atrial fibrillation...
  2. McMurray J, Holman R, Haffner S, Bethel M, Holzhauer B, Hua T, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1477-90 pubmed publisher
    ..with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors to receive valsartan (up to 160 mg daily) or placebo (and nateglinide or placebo) in addition to lifestyle modification...
  3. Peeters A, Netea M, Kullberg B, Thien T, van der Meer J. The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production. Immunology. 1998;94:376-9 pubmed
    ..as the angiotensin-converting enzyme (ACE)-inhibitor captopril and the angiotensin II receptor type I antagonist valsartan, have potent inhibitory effects on the lipopolysaccharide (LPS)-stimulated production of pro-inflammatory ..
  4. Zaritsky J, Kalantar Zadeh K. The crossroad of RAAS modulation, inflammation, and oxidative stress in dialysis patients: light at the end of the tunnel?. J Am Soc Nephrol. 2012;23:189-91 pubmed publisher
  5. Bruder Nascimento T, Chinnasamy P, Riascos Bernal D, Cau S, Callera G, Touyz R, et al. Angiotensin II induces Fat1 expression/activation and vascular smooth muscle cell migration via Nox1-dependent reactive oxygen species generation. J Mol Cell Cardiol. 2014;66:18-26 pubmed
    ..kinases 1/2 (Erk1/2) inhibitor PD98059 (1 ?mol/L), or Ang II type 1 receptor (AT1R) valsartan (1 ?mol/L). siRNA was used to knockdown Nox1 or Fat1. Cell migration was determined by Boyden chamber assay...
  6. Yang W, Hu X, Han H, Shi L, Feng G, Liu Y, et al. The effects of valsartan on cognitive deficits induced by aluminum trichloride and d-galactose in mice. Neurol Res. 2014;36:651-8 pubmed publisher
    b>Valsartan has been reported to reduce brain beta-amyloid protein levels and improve spatial learning in the Tg2576 transgenic mouse model of Alzheimer's disease (AD)...
  7. Paton D. Nebivolol/valsartan: Fixed-dose combination for treatment of hypertension. Drugs Today (Barc). 2017;53:19-26 pubmed publisher
    ..that a fixed-dose combination (FDC) of the beta-blocker nebivolol (5 mg) and the angiotensin II antagonist valsartan (80 mg) produced a significant reduction of both diastolic and systolic blood pressure in patients with ..
  8. Ho C, McMurray J, Cirino A, Colan S, Day S, Desai A, et al. The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial. Am Heart J. 2017;187:145-155 pubmed publisher
    ..Participants are randomly assigned to receive valsartan 80 to 320 mg daily (depending on age and weight) or placebo...
  9. Yeom D, Chae B, Son H, Kim J, Chae J, Song S, et al. Enhanced oral bioavailability of valsartan using a polymer-based supersaturable self-microemulsifying drug delivery system. Int J Nanomedicine. 2017;12:3533-3545 pubmed publisher
    ..drug delivery system (S-SMEDDS) was successfully formulated to enhance the dissolution and oral absorption of valsartan (VST), a poorly water-soluble drug, while reducing the total quantity for administration...

More Information

Publications15

  1. Shamardl H, El Ashmony S, Kamel H, Fatani S. Potential Cardiovascular and Renal Protective Effects of Vitamin D and Coenzyme Q10 in l-NAME-Induced Hypertensive Rats. Am J Med Sci. 2017;354:190-198 pubmed publisher
    ..effects of vit D and COQ10 both separately and in combination with an angiotensin II receptor blocker, valsartan (vals) in l-NAME hypertensive rats. Hypertension was induced in rats by l-NAME administration...
  2. Holman R, Haffner S, McMurray J, Bethel M, Holzhauer B, Hua T, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1463-76 pubmed publisher
    ..factors to receive nateglinide (up to 60 mg three times daily) or placebo, in a 2-by-2 factorial design with valsartan or placebo, in addition to participation in a lifestyle modification program...
  3. Filippatos G, Farmakis D, Parissis J, Lekakis J. Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice. BMC Med. 2015;13:35 pubmed publisher
    ..recent PARADIGM-HF trial compared the novel compound LCZ696, a combination of the angiotensin receptor blocker valsartan and the neprilysin inhibitor sacubitril, versus the angiotensin-converting enzyme inhibitor enalapril in 8,442 ..
  4. Ibrahim D, Radwan R, Abdel Fattah S. Antioxidant and antiapoptotic effects of sea cucumber and valsartan against doxorubicin-induced cardiotoxicity in rats: The role of low dose gamma irradiation. J Photochem Photobiol B. 2017;170:70-78 pubmed publisher
    ..This study was conducted to evaluate the cardioprotective effect of sea cucumber and valsartan against DOX-induced cardiotoxicity in rats...
  5. Senni M, Trimarco B, Emdin M, De Biase L. [Sacubitril/valsartan, a new and effective treatment for heart failure with reduced ejection fraction]. G Ital Cardiol (Rome). 2017;18:3-11 pubmed publisher
    ..study, the largest outcome trial in HFrEF, has shown improved cardiovascular outcomes with sacubitril/valsartan (Entresto®, Novartis), previously known as LCZ696, compared with angiotensin-converting enzyme (ACE) inhibitor ..
  6. Lewis E, Claggett B, McMurray J, Packer M, Lefkowitz M, Rouleau J, et al. Health-Related Quality of Life Outcomes in PARADIGM-HF. Circ Heart Fail. 2017;10: pubmed publisher
    ..Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure), sacubitril/valsartan reduced morbidity and mortality compared with enalapril. Another major treatment goal is to improve HRQL...